NANOSYRINGE
"NANOSYRINGE" is a word mark owned by Nanosyrinx Ltd, filed at the USPTO on March 10, 2026. It is waiting to be published and covers classes 1, 5 and 42.
- Status
- Awaiting publication
- Since October 22, 2026
- Filed
- March 10, 2026
- Registered
- November 10, 2026
- Expires
- Not recorded
- Application no.
- 99693310
- Registration no.
- Not yet
- Office
- USPTO
- United States Patent and Trademark Office
- Mark type
- Word mark
- 3 classes
Who owns NANOSYRINGE
The owner and representative on file with the office.
Owner
Nanosyrinx Ltd
West Midlands, United Kingdom
Representative
Jordan Arnot Leahey
CM Law PLLC
What the mark covers
The products and services NANOSYRINGE is filed for, grouped by Nice class.
cultures of micro-organisms, other than for medical and veterinary use, namely, for the targeted intracellular delivery of biological molecules; Chemical substances for analyses in laboratories, for use in science, industry, and for in vitro use for the targeted intracellular delivery of biological molecules; cell culture media for scientific and research purposes, namely, use in cell cultures for the targeted intracellular delivery of biological molecules; cell culture media for use in the biotechnological industry, other than for medical or veterinary purposes; nutritive substances for microorganism cultures, other than for medical or veterinary purposes, namely, for processing living cells for the targeted intracellular delivery of biological molecules; Active chemical ingredients and unprocessed polymers for use in the manufacture, development and testing of pharmaceuticals for the targeted intracellular delivery of biological molecules and for analysis in laboratories; proteins in raw material form for scientific research; peptide substrates for scientific purposes; protein in raw material form for scientific and medical research in the intracellular delivery of biological molecules; diagnostic reagents for scientific use for the targeted intracellular delivery of biological molecules, peptides, proteins, enzymes, gene editing enzymes, antibodies or antibody fragments; genetically-encoded protein complexes and protein assemblies, supplied in raw material form, supplied in an intermediate semi-processed form, or supplied in conjunction with buffer solutions or reagents, capable of binding to cell-surface antigens, for delivering biological molecules to target cells, for the purposes of scientific and medical research
Pharmaceutical preparations for the targeted intracellular delivery of biological molecules, drugs, and therapeutic substances, namely, those containing peptides, proteins, enzymes, gene editing enzymes, antibodies, antibody fragments and genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens, vaccines, and those for the treatment and prevention of metabolic diseases, diabetes, obesity, dyslipidemia, fibrotic diseases, liver disease, lung disease, kidney fibrosis, rare diseases, orphan diseases, cancer, genetic diseases, autoimmune diseases, neurological diseases, infectious diseases, cardiovascular diseases, neoplastic diseases, respiratory diseases, endocrine diseases, inflammatory diseases, musculoskeletal disorders, gastrointestinal and hepatic diseases, renal and urological diseases, reproductive diseases, gynecological disorders, dermatological diseases, ophthalmic diseases, hematological disorders, or diseases affecting the organs; Pharmaceutical and veterinary preparations for use in connection with intracellular delivery of drugs, antibodies and antibody fragments, enzymes, nucleic acids, proteins, peptides, small molecules, therapeutic substances focused on non-viral delivery technology for the treatment and prevention of metabolic diseases, diabetes, obesity, dyslipidemia, fibrotic diseases, liver disease, lung disease, kidney fibrosis, rare diseases, orphan diseases, cancer, genetic diseases, autoimmune diseases, neurological diseases, infectious diseases, cardiovascular diseases, neoplastic diseases, respiratory diseases, endocrine diseases, inflammatory diseases, musculoskeletal disorders, gastrointestinal and hepatic diseases, renal and urological diseases, reproductive diseases, gynecological disorders, dermatological diseases, ophthalmic diseases, hematological disorders, or diseases affecting the organs; Pharmaceutical preparations for gene editing for the treatment and prevention of metabolic diseases, diabetes, obesity, dyslipidemia, fibrotic diseases, liver disease, lung disease, kidney fibrosis, rare diseases, orphan diseases, cancer, genetic diseases, autoimmune diseases, neurological diseases, infectious diseases, cardiovascular diseases, neoplastic diseases, respiratory diseases, endocrine diseases, inflammatory diseases, musculoskeletal disorders, gastrointestinal and hepatic diseases, renal and urological diseases, reproductive diseases, gynecological disorders, dermatological diseases, ophthalmic diseases, hematological disorders, or diseases affecting the organs; pharmaceutical preparations for intracellular delivery of drugs, nucleic acids, proteins, peptides, therapeutic substances focused on the development of RNA therapies, therapeutic substances focused on non-viral delivery technology for the treatment and prevention of metabolic diseases, diabetes, obesity, dyslipidemia, fibrotic diseases, liver disease, lung disease, kidney fibrosis, rare diseases, orphan diseases, cancer, genetic diseases, autoimmune diseases, neurological diseases, infectious diseases, cardiovascular diseases, neoplastic diseases, respiratory diseases, endocrine diseases, inflammatory diseases, musculoskeletal disorders, gastrointestinal and hepatic diseases, renal and urological diseases, reproductive diseases, gynecological disorders, dermatological diseases, ophthalmic diseases, hematological disorders, or diseases affecting the organs; drug delivery agents in the form of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens, that facilitate the delivery of pharmaceutical preparations for the targeted intracellular delivery of biological molecules, drugs, therapeutics, and pharmaceutical preparations, and for delivering pharmaceuticals to target cells; biologics in the nature of pharmaceutical preparations in the nature of intracellular delivery of biological molecules, drugs and therapeutics for the treatment and prevention of metabolic diseases, diabetes, obesity, dyslipidemia, fibrotic diseases, liver disease, lung disease, kidney fibrosis, rare diseases, orphan diseases, cancer, genetic diseases, autoimmune diseases, neurological diseases, infectious diseases, cardiovascular diseases, neoplastic diseases, respiratory diseases, endocrine diseases, inflammatory diseases, musculoskeletal disorders, gastrointestinal and hepatic diseases, renal and urological diseases, reproductive diseases, gynecological disorders, dermatological diseases, ophthalmic diseases, hematological disorders, or diseases affecting the organs; Drug delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceuticals, proteins and peptides to target cells; bacterial preparations for pharmaceutical and medical purposes for the targeted intracellular delivery of biological molecules, drugs and therapeutics; cultures of micro-organisms for medical and veterinary use; cell culture media for medical purposes, namely for the storage of micro-organisms, bacteria, and bacteriological cultures; nutritive substances for micro-organisms for medical purposes; bacterial and bacteriological preparations for veterinary use; pharmaceutical and veterinary preparations targeted at intracellular delivery of biological molecules, drugs and therapeutics for the treatment and prevention of metabolic diseases, diabetes, obesity, dyslipidemia, fibrotic diseases, liver disease, lung disease, kidney fibrosis, rare diseases, orphan diseases, cancer, genetic diseases, autoimmune diseases, neurological diseases, infectious diseases, cardiovascular diseases, neoplastic diseases, respiratory diseases, endocrine diseases, inflammatory diseases, musculoskeletal disorders, gastrointestinal and hepatic diseases, renal and urological diseases, reproductive diseases, gynecological disorders, dermatological diseases, ophthalmic diseases, hematological disorders, or diseases affecting the organs; diagnostic preparations for medical purposes; Biological preparations for use in cell cultures for medical and veterinary purposes; nutrients for cell cultures being nutrient preparations sold as a component ingredient of for cultivating drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; living cells for medical use; genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens, for delivering biological molecules to target cells, for use as pharmaceutical and drug delivery agents
Scientific and technological services, namely scientific and medical research and new product design services in the fields of biology, medicine, pharmaceuticals, drug delivery, biotechnology, gene editing, drug discovery, and vaccines; medical research laboratory services, pharmaceutical research and development relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; Conducting clinical trials for others relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; drug discovery services relating to the targeted intracellular delivery of biological molecules, drugs, and therapeutics; pharmaceutical laboratory research services relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; Medical research services in the fields of metabolic diseases, diabetes, obesity, dyslipidemia, fibrotic diseases, liver disease, lung disease, kidney fibrosis, rare diseases, orphan diseases, cancer, genetic diseases, autoimmune diseases, neurological diseases, infectious diseases, cardiovascular diseases, neoplastic diseases, respiratory diseases, endocrine diseases, inflammatory diseases, musculoskeletal disorders, gastrointestinal and hepatic diseases, renal and urological diseases, reproductive diseases, gynecological disorders, dermatological diseases, ophthalmic diseases, hematological disorders, or diseases affecting the organs relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; Scientific research in the field of pharmacy relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; Research and development of vaccines relating to the targeted intracellular delivery of biological molecules, drugs, and therapeutics; Scientific investigations for medical purposes relating to the targeted intracellular delivery of biological molecules, drugs, and therapeutics; development of pharmaceutical preparations and medicines; pharmaceutical drug development services for the targeted intracellular delivery of biological molecules, drugs and therapeutics; medical research laboratory services; providing medical and scientific research information in the field of pharmaceuticals and clinical trials relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics, and in the field of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens, for delivering biological molecules, drugs and therapeutics to target cells; research and development in the fields of gene editing and drug delivery relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; scientific and technological services and research and design, and biotechnological research services, drug discovery services, clinical trials, laboratory research services, medical research, pharmaceutical drug development services, pharmaceutical research and development, all relating to genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens, for delivering biological molecules, drugs and therapeutics to target cells; research and development of vaccines and medicines relating to, and in the field of drug delivery relating to, genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens, for delivering biological molecules, drugs and therapeutics to target cells; information, advisory and consultancy services relating to all of the aforesaid
What has happened so far
Steps recorded by the USPTO, newest first.
- Approved for registration supplemental register
- Notification of examiners amendment e-mailed
- Examiner's amendment entered
- Examiners amendment e-mailed
- Examiners amendment -written
- Teas/email correspondence entered
- Correspondence received in law office
- Teas response to office action received
- Notification of non-final action e-mailed
- Non-final action e-mailed
8 earlier steps on the official record.
About NANOSYRINGE
Who owns the trademark "NANOSYRINGE"?
The USPTO trademark "NANOSYRINGE" (application 99693310) is owned by Nanosyrinx Ltd.
What is the status of "NANOSYRINGE"?
Its status at the USPTO is: awaiting publication.
When was "NANOSYRINGE" registered?
It was registered on November 10, 2026.
Get this data via the API
Everything on this page comes from the Signa API. Pull NANOSYRINGE and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_019d3ee7-b175-7447-a705-98334a3a7bf9
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_019d3ee7-b175-7447-a705-98334a3a7bf9",
"object": "trademark",
"mark_text": "NANOSYRINGE",
"status": {
"primary": "pending",
"stage": "pending_publication"
},
"office_code": "US",
"application_number": "99693310",
"filing_date": "2026-03-10",
"nice_classes": [
1,
5,
42
],
"owners": [
{
"name": "NANOSYRINX LTD",
"entity_id": null
}
]
}